Milestone Scientific Inc. (MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that three members of its Board of Directors have converted $465,000 of outstanding loans owed by the Company into common stock, eliminating the Company’s outstanding note payable and resulting in a debt-free balance sheet.

The debt-to-equity conversion was completed effective August 19, 2026 at a rate of $0.50 per share, representing a 6.4% premium to the Company’s closing market price of $0.47 per share on August 19, 2026. The conversion resulted in the issuance of 976,870 shares of common stock to the participating directors.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.